1427 completed, 327 recruiting, 322 terminated, 252 unknown. 2692 Phase 2, 490 Phase 1, 259 Phase 3.
Follow Autoimmune Diseases: new trials by email Literature Review of Autoimmune Diseases trials Research Report on Autoimmune Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabichromene Safety in Rheumatoid Arthritis Cannabichromene - Arthritis, Rheumatoid | Phase 1 / Phase 2 | Withdrawn | Crystal Lederhos Smith | 2028-07-15 | 2026-09-23 | |
| Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 10 | 2028-02-01 | 2026-04-13 |
| GLP-1 RA for Stage 1 Type 1 Diabetes Semaglutide, Placebo - Stage 1 Diabetes Mellitus, Type 1 | Phase 2 | Not yet recruiting | Children's Hospital Medical Center, Cincinnati | 15 | 2027-09-01 | 2026-02-24 |
| Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells fetal MSCs combined with 4SCAR T cells - Autoimmune Diseases | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| CAR-T Cells Targeting Autoimmune Diseases 4SCAR T cells - Autoimmune Diseases | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-11-02 |
| A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC - Autoimmune Encephalitis (AE) | Phase 2 | Not yet recruiting | argenx | 170 | 2027-04-01 | 2026-09-22 |
| A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive | Phase 2 | Not yet recruiting | Moein Amin | 20 | 2027-03-01 | 2026-08-19 |
| A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 36 | 2027-02-08 | 2026-06-25 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | AbelZeta Inc. | 119 | 2027-02-01 | 2026-10-13 |
| The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE. belantamab mafodotin to the existing stable standard background therapy - SLE - Systemic Lupus Erythematosus | Phase 2 | Not yet recruiting | Medical Association for the Study of Cancer Biology and Treatment | 12 | 2027-02-01 | 2026-09-28 |
| Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring. Sotagliflozin initiation - Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM) | Phase 2 | Not yet recruiting | HealthPartners Institute | 80 | 2027-01-01 | 2026-10-23 |
| SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. Recombinant Zoster Vaccine (Shingrix; RZV), Semaglutide (Ozempic®), Placebo (saline injection) - Type 1 Diabetes Mellitus | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 240 | 2027-01-01 | 2026-05-29 |
| Verapamil In Preclinical Type 1 Diabetes Verapamil 120 Mg/24 Hours Oral Capsule, Extended Release, Placebo, blood sampling - Type 1 Diabetes | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2027-01-01 | 2026-10-22 |
| dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin - Type 1 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 | Not yet recruiting | University Medical Center Groningen | 36 | 2027-01-01 | 2026-10-20 |
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis VIS954, Standard Of Care (SOC), Placebo - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 75 | 2026-12-15 | 2026-10-29 |
| Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis ABBV-722, Upadacitinib - Rheumatoid Arthritis | Phase 2 | Not yet recruiting | AbbVie | 250 | 2026-12-07 | 2026-11-10 |
| Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease Infliximab 0.1%, Loteprednol - Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis | Phase 2 | Not yet recruiting | Instituto de Oftalmología Fundación Conde de Valenciana | 38 | 2026-12-01 | 2026-06-26 |
| Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 20 | 2026-12-01 | 2026-10-16 |
| Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity Tirzepatide - Type 1 Diabetes Mellitus, Overweight and Obesity | Phase 2 | Not yet recruiting | Royal North Shore Hospital | 40 | 2026-12-01 | 2025-07-29 |
Showing 20 of 2692. Sign in to see all of them.
Arthritis, Rheumatoid (568) · Diabetes Mellitus, Type 1 (514) · Multiple Sclerosis (382) · Lupus Erythematosus, Systemic (268) · Purpura, Thrombocytopenic, Idiopathic (166) · Multiple Sclerosis, Relapsing-Remitting (119) · Diabetes Mellitus (104) · Lupus Nephritis (100) · Glomerulonephritis, IGA (83) · Sjogren's Syndrome (78) · Multiple Sclerosis, Chronic Progressive (75) · Hypoglycemia (59) · Myasthenia Gravis (57) · Arthritis (53)
Immune System Diseases (2652) · Skin and Connective Tissue Diseases (1109) · Connective Tissue Diseases (978) · Musculoskeletal Diseases (699) · Nervous System Diseases (694) · Joint Diseases (667) · Rheumatic Diseases (660) · Autoimmune Diseases of the Nervous System (627) · Arthritis (624) · Endocrine System Diseases (587) · Nutritional and Metabolic Diseases (544) · Demyelinating Diseases (531) · Metabolic Diseases (528) · Glucose Metabolism Disorders (510)
Rituximab (108) · Methotrexate (82) · Prednisone (58) · Cyclophosphamide (54) · Mycophenolic Acid (47) · Insulin (46) · Methylprednisolone (40) · Abatacept (33) · Adalimumab (26) · Dexamethasone (26) · Etanercept (25) · Sodium Chloride (25) · Antilymphocyte Serum (24) · Saline Solution (24) · Sirolimus (24)
Novartis Pharmaceuticals (63) · National Institute of Allergy and Infectious Diseases (NIAID) (58) · Peking University People's Hospital (48) · GlaxoSmithKline (41) · Amgen (36) · Biogen (36) · Pfizer (31) · Eli Lilly and Company (29) · Institute of Hematology & Blood Diseases Hospital, China (28) · Assistance Publique - Hôpitaux de Paris (26) · Hoffmann-La Roche (25) · Sanofi (25) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (24) · AstraZeneca (22) · Bristol-Myers Squibb (22)
United States (1224) · Germany (370) · China (351) · Poland (343) · Spain (314) · Canada (310) · United Kingdom (307) · Italy (235) · France (229) · Czechia (195) · Hungary (184) · Mexico (176) · Russia (169) · Belgium (162) · Australia (150)
Lei Zhang, MD (14) · Richard Burt, MD (10)
PMID 33687069, PMID 38299639, PMID 32816215, PMID 33127856, PMID 34870800, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36931693, PMID 39192350, PMID 25047021, PMID 28143815, PMID 38958913, PMID 31072380, PMID 40465397, PMID 19005394, PMID 37528520, PMID 39735417, PMID 23438305, PMID 24802773, PMID 26275429, PMID 28941219, PMID 34091488, PMID 34724566, PMID 34778952, PMID 26032537, PMID 26241693, PMID 29463520, PMID 29958797, PMID 30842122, PMID 34041702, PMID 34706874, PMID 35179437, PMID 35797241, PMID 36205910, PMID 36418156, PMID 37345645, PMID 37453736, PMID 37747626, PMID 39899371, PMID 12542793, PMID 15864738, PMID 19404957, PMID 20003758, PMID 20926833, PMID 20937945, PMID 22067384, PMID 22622860, PMID 22674457, PMID 23254770
2025 (40), 2023 (36), 2018 (30), 2014 (28), 2016 (24), 2019 (24), 2009 (23), 2015 (21), 2017 (15), 2008 (10), 2005 (7), 2004 (5), U01DK061055 (4), UC4DK097835 (4), UC4DK106993 (4)